UK Liver Diseases Therapeutics Market Report 2022 to 2030

UK Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the UK Liver Disease Therapeutics market will reach a value of $803 Mn from $600 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030. Liver Disease Therapeutics in the UK is dominated by a few domestic pharmaceutical companies such as Intercept Pharmaceuticals, Gilead Sciences, AstraZeneca and Shire. The Liver Disease Therapeutics market in the UK is segmented into different types of disease and different therapy types. Some of the major factors affecting the UK Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10GBPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Dr. Vishwa Modhia

Buy Now

UK Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the UK Liver Disease Therapeutics market will reach a value of $803 Mn from $600 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030.

The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. Liver disease is the fifth leading cause of mortality in the United Kingdom and the only major cause of death that is on the rise. According to the most recent WHO data, 7,666 people died from liver disease in the United Kingdom in 2020, accounting for 1.50 % of all deaths.

With an age-adjusted death rate of 7.90 per 100,000 inhabitants, the United Kingdom ranks 142nd in the world. 90% of liver disease in the UK is caused by alcohol, obesity, and viral hepatitis, and is thus preventable. Every year, approximately 1000 liver transplants are performed. At any given time, 350 patients are waiting for a liver transplant. UK's government spends 12 % of its GDP on healthcare.

UK Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

In the United Kingdom, the prevalence of liver illnesses is rising. 63 % of UK adults are now classified as obese or overweight, and one in every three has the early-stage non-alcohol-related fatty liver disease (NAFLD). Viral hepatitis affects approximately 215,000 persons in the United Kingdom, with approximately half of these cases going untreated. Pharmaceuticals is a cutting-edge industry in the United Kingdom. These aspects could boost the UK Liver Disease Therapeutics market.

Market Restraints

People from lower socioeconomic origins are disproportionately affected by the liver disease because they are more prone to engage in risky behaviours such as heavy alcohol intake and bad diets. Low productivity and a lack of training in the United Kingdom are not conducive to innovation. While developing new pharmaceuticals and cures, it is necessary to follow regulatory rules established by organisations such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These criteria can be complicated and time-consuming, resulting in delays and higher expenses. These factors may deter new entrants into the UK Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Gilead Sciences: Gilead Sciences is a leading biopharmaceutical company that specializes in the development of innovative treatments for liver diseases such as hepatitis B and C, liver cancer, and non-alcoholic steatohepatitis (NASH)
Intercept Pharmaceuticals: Intercept Pharmaceuticals is a biopharmaceutical company that focuses on the development of therapeutics for chronic liver diseases such as primary biliary cholangitis (PBC) and NASH
AstraZeneca: AstraZeneca is a global pharmaceutical company that develops and markets drugs for various diseases including liver diseases such as primary sclerosing cholangitis (PSC) and NASH
GlaxoSmithKline: GlaxoSmithKline is a global healthcare company that focuses on the development of innovative treatments for liver diseases such as hepatitis B and C
Shire: Shire is a biotechnology company that develops and markets treatments for rare diseases, including rare liver diseases such as hereditary angioedema and Wilson's disease
Merck Sharp & Dohme: Merck Sharp & Dohme is a global pharmaceutical company that develops and markets drugs for various diseases including liver diseases such as hepatitis C and NASH
AbbVie: AbbVie is a biopharmaceutical company that focuses on the development of innovative treatments for liver diseases such as hepatitis C and NASH

Recent Notable Updates

January 2023: Intercept Pharmaceuticals, a biopharmaceutical company, said that the FDA has approved Intercept's New Drug Application (NDA) for obeticholic acid (OCA), which seeks fast clearance for the treatment of patients with pre-cirrhotic liver fibrosis caused by non-alcoholic steatohepatitis (NASH). The FDA stated that this is a comprehensive Class 2 resubmission and has assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of June 2023. The FDA's schedule for reviewing the NDA is still open to change.

Healthcare Policies and Reimbursement Scenarios

In the UK, liver disease therapeutics are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA), which is responsible for ensuring the safety, quality, and efficacy of medicines. The MHRA evaluates the clinical data on new drugs and decides whether to approve them for use in the UK market. The National Institute for Health and Care Excellence (NICE) is responsible for evaluating the cost-effectiveness of new drugs and making recommendations to the NHS on whether to reimburse them.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.